Seward announces merger and restructuring plans to establish FermionX Ltd
Merger with sister company, C-Tech Electronics Ltd, to form a new vertically integrated manufacturing company.
Seward, makers of Stomacher laboratory blenders and Insterprep sterile media, has merged with its sister company, C-Tech Electronics Ltd, to form a new vertically integrated manufacturing company called FermionX Ltd. There will be no change to Seward’s name; and its high standard of operations known and expected by its customers will also remain the same, but with the added benefit of increased technical resource for R&D, customer support and manufacturing.
The merger represents a significant development for stakeholders, creating a company with combined turnover of circa £6 million. This move consolidates two companies with shared core values on strong customer relationships, quality and value-added products and service.
FermionX will continue to operate through its individual brands; Seward, manufacturers of globally renowned Stomacher lab blenders, and C-Tech Electronics, providing comprehensive electronic contract manufacturing services. The company will leverage both brands’ respective strengths for the benefit of its customers with greater resources for manufacturing, R&D and global sales and distribution footprint.
The merger provides a greater technical resource for Seward to enhance its R&D strategy, an area which has gained emphasis recently with the launch of the Stomacher 400 EVO laboratory blender and Insterprep range of pre-weighed, sterile media.
Under the C-Tech Electronics brand, the company has a highly successful and flexible manufacturing service, providing comprehensive contract electronic manufacturing solutions with expertise and experience from PCB design to complete box-build.
The new company will be led by John Patrick, whose family started C-Tech Electronics. Mr Patrick said: “Establishing FermionX Ltd is an immensely exciting step, developing a company that can provide end-to-end electronic manufacturing solutions, with a final product mind-set. The consolidated resource from all companies will allow us to quickly respond to market opportunities and technology trends to better support our customers.” He added: “While FermionX provides the overriding corporate structure, all company brands will continue to be presented under their existing brand names and to the same high standards of products and service.”
Former Managing Director of Seward, Daniel Crothers, remains with the company as Sales and Marketing Director. Mr Crothers continued: “Seward enjoys a global reputation for quality laboratory products. Under FermionX, the Seward brand will continue to enhance this reputation with emphasis on new product development that adds real value to our laboratory customers. We already have a project list for planned launches in 2017 which our distribution partners are very excited about.”
Technical Director Stuart Ray, who will be heading up the R&D team said: “Both companies have collaborated over the years on product design and development with customers and other strategic partners, FermionX will allow this function to expand and drive the growth of our brands and of the business in general.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance